Inhibition of human mu-calpain by conformationally constrained calpastatin peptides

Pfizer J, Assfalg-Machleidt I, Machleidt W, Schaschke N (2008)
BIOLOGICAL CHEMISTRY 389(1): 83-90.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Pfizer, Jose; Assfalg-Machleidt, Irmgard; Machleidt, Werner; Schaschke, NorbertUniBi
Abstract / Bemerkung
The 27-mer peptide CP1 B-[1-27] derived from exon 1B of calpastatin stands out among the known inhibitors for mu- and m-calpain due to its high potency and selectivity. By systematical truncation, a 20-mer peptide, CP1B-[4-23], was identified as the core sequence required to maintain the affinity/selectivity profile of CP1B-[1-27]. Starting with this peptide, the turn-like region Glu(10)(i)-Leu(11)(i+1)-Gly(12)(i+2)-Lys(13)(i +3) was investigated. Sequence alignment of subdomains 1B, 2B, 3B and 4B from different mammalians revealed that the amino acid residues in position i+1 and i+2 are almost invariably flanked by oppositely charged residues, pointing towards a turn-like conformation stabilized by salt bridge/H-bond interaction. Accordingly, using different combinations of acidic and basic residues in position i and i+3, a series of conformationally constrained variants of CP1 B-[4-23] were synthesized by macrolactamization utilizing the side chain functionalities of these residues. With the combination of Glu(i)/Dab(i+3), the maximum of conformational rigidity without substantial loss in affinity/selectivity was reached. These results clearly demonstrate that the linear peptide chain corresponding to subdomain 1B reverses its direction in the region Glu(10)-Lys(13) upon binding to mu-calpain, and thereby adopts a loop-like rather than a tight turn conformation at this site.
Stichworte
macrolactamization; cysteine protease; peptidomimetic; inhibitor; protease
Erscheinungsjahr
2008
Zeitschriftentitel
BIOLOGICAL CHEMISTRY
Band
389
Ausgabe
1
Seite(n)
83-90
ISSN
1431-6730
eISSN
1437-4315
Page URI
https://pub.uni-bielefeld.de/record/2403720

Zitieren

Pfizer J, Assfalg-Machleidt I, Machleidt W, Schaschke N. Inhibition of human mu-calpain by conformationally constrained calpastatin peptides. BIOLOGICAL CHEMISTRY. 2008;389(1):83-90.
Pfizer, J., Assfalg-Machleidt, I., Machleidt, W., & Schaschke, N. (2008). Inhibition of human mu-calpain by conformationally constrained calpastatin peptides. BIOLOGICAL CHEMISTRY, 389(1), 83-90. https://doi.org/10.1515/BC.2008.004
Pfizer, Jose, Assfalg-Machleidt, Irmgard, Machleidt, Werner, and Schaschke, Norbert. 2008. “Inhibition of human mu-calpain by conformationally constrained calpastatin peptides”. BIOLOGICAL CHEMISTRY 389 (1): 83-90.
Pfizer, J., Assfalg-Machleidt, I., Machleidt, W., and Schaschke, N. (2008). Inhibition of human mu-calpain by conformationally constrained calpastatin peptides. BIOLOGICAL CHEMISTRY 389, 83-90.
Pfizer, J., et al., 2008. Inhibition of human mu-calpain by conformationally constrained calpastatin peptides. BIOLOGICAL CHEMISTRY, 389(1), p 83-90.
J. Pfizer, et al., “Inhibition of human mu-calpain by conformationally constrained calpastatin peptides”, BIOLOGICAL CHEMISTRY, vol. 389, 2008, pp. 83-90.
Pfizer, J., Assfalg-Machleidt, I., Machleidt, W., Schaschke, N.: Inhibition of human mu-calpain by conformationally constrained calpastatin peptides. BIOLOGICAL CHEMISTRY. 389, 83-90 (2008).
Pfizer, Jose, Assfalg-Machleidt, Irmgard, Machleidt, Werner, and Schaschke, Norbert. “Inhibition of human mu-calpain by conformationally constrained calpastatin peptides”. BIOLOGICAL CHEMISTRY 389.1 (2008): 83-90.

5 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Atrial Calpains: Mediators of Atrialmyopathies in Atrial Fibrillation.
Bukowska A, Lendeckel U, Goette A., J Atr Fibrillation 6(6), 2014
PMID: 27957058
Physiologic and pathophysiologic role of calpain: implications for the occurrence of atrial fibrillation.
Bukowska A, Lendeckel U, Bode-Böger SM, Goette A., Cardiovasc Ther 30(3), 2012
PMID: 21108772
Development of α-helical calpain probes by mimicking a natural protein-protein interaction.
Jo H, Meinhardt N, Wu Y, Kulkarni S, Hu X, Low KE, Davies PL, DeGrado WF, Greenbaum DC., J Am Chem Soc 134(42), 2012
PMID: 22998171
A novel calpastatin-based inhibitor improves postischemic neurological recovery.
Anagli J, Han Y, Stewart L, Yang D, Movsisyan A, Abounit K, Seyfried D., Biochem Biophys Res Commun 385(1), 2009
PMID: 19422795
Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin.
Hanna RA, Campbell RL, Davies PL., Nature 456(7220), 2008
PMID: 19020623

25 References

Daten bereitgestellt von Europe PubMed Central.

Synthesis of cell-penetrating conjugates of calpain activator peptides.
Banoczi Z, Tantos A, Farkas A, Tompa P, Friedrich P, Hudecz F., Bioconjug. Chem. 18(1), 2007
PMID: 17226965
Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT.
Betts R, Weinsheimer S, Blouse GE, Anagli J., J. Biol. Chem. 278(10), 2002
PMID: 12500971
A survey of calpain inhibitors.
Donkor IO., Curr. Med. Chem. 7(12), 2000
PMID: 11032966
Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin.
Gil-Parrado S, Assfalg-Machleidt I, Fiorino F, Deluca D, Pfeiler D, Schaschke N, Moroder L, Machleidt W., Biol. Chem. 384(3), 2003
PMID: 12715890
The calpain system.
Goll DE, Thompson VF, Li H, Wei W, Cong J., Physiol. Rev. 83(3), 2003
PMID: 12843408
Calpastatin simultaneously binds four calpains with different kinetic constants.
Hanna RA, Garcia-Diaz BE, Davies PL., FEBS Lett. 581(16), 2007
PMID: 17543955
Structure of the active 27-residue fragment of human calpastatin.
Ishima R, Tamura A, Akasaka K, Hamaguchi K, Makino K, Murachi T, Hatanaka M, Maki M., FEBS Lett. 294(1-2), 1991
PMID: 1743294

Kawasaki, J. Biochem. (Tokyo) 106(), 1989
A circular dichroism study of preferential hydration and alcohol effects on a denatured protein, pig calpastatin domain I.
Konno T, Tanaka N, Kataoka M, Takano E, Maki M., Biochim. Biophys. Acta 1342(1), 1997
PMID: 9366272
Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene.
Maki M, Bagci H, Hamaguchi K, Ueda M, Murachi T, Hatanaka M., J. Biol. Chem. 264(32), 1989
PMID: 2553724

AUTHOR UNKNOWN, 0
Binding-induced folding transitions in calpastatin subdomains A and C.
Mucsi Z, Hudecz F, Hollosi M, Tompa P, Friedrich P., Protein Sci. 12(10), 2003
PMID: 14500891

Sorimachi, J. Biochem. (Tokyo) 129(), 2001
The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium.
Strobl S, Fernandez-Catalan C, Braun M, Huber R, Masumoto H, Nakagawa K, Irie A, Sorimachi H, Bourenkow G, Bartunik H, Suzuki K, Bode W., Proc. Natl. Acad. Sci. U.S.A. 97(2), 2000
PMID: 10639123
Bicyclic homodetic peptide libraries: comparison of synthetic strategies for their solid-phase synthesis.
Teixido M, Altamura M, Quartara L, Giolitti A, Maggi CA, Giralt E, Albericio F., J Comb Chem 5(6), 2003
PMID: 14606803
Intrinsically unstructured proteins.
Tompa P., Trends Biochem. Sci. 27(10), 2002
PMID: 12368089
Calpastatin subdomains A and C are activators of calpain.
Tompa P, Mucsi Z, Orosz G, Friedrich P., J. Biol. Chem. 277(11), 2002
PMID: 11809743
Characterization of a functional domain of human calpastatin.
Uemori T, Shimojo T, Asada K, Asano T, Kimizuka F, Kato I, Maki M, Hatanaka M, Murachi T, Hanzawa H., Biochem. Biophys. Res. Commun. 166(3), 1990
PMID: 2407243

AUTHOR UNKNOWN, 0
Interaction of calpastatin with calpain: a review.
Wendt A, Thompson VF, Goll DE., Biol. Chem. 385(6), 2004
PMID: 15255177
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 18095873
PubMed | Europe PMC

Suchen in

Google Scholar